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Abstract Increased concentrations of procalcitonin (PCT) are
found in the plasma of patients with thermal injury and in
patients with sepsis and severe infection, making this molecule
important as a diagnostic and prognostic marker in these
diseases. Interestingly, only the truncated form of PCT,
PCT(3-116), is present in the plasma of these patients. The
enzyme responsible for this truncation is unknown as yet. Here,
using capillary zone electrophoresis, mass spectrometry and
Edman sequence analysis, we demonstrate that dipeptidyl
peptidase IV (DP IV, EC 3.4.14.5) is capable of catalyzing the
hydrolysis of PCT(1-116), releasing the N-terminal dipeptide
Ala-Pro. We hypothesize that PCT(3-116) is the result of the
hydrolysis of PCT(1-116) by soluble DP IV of the blood plasma
or by DP IV expressed on the surface of cells.
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1. Introduction
Procalcitonin (PCT), a species-speci¢c propeptide of calci-
tonin, is a protein of 116 amino acids with a molecular weight
of 13 kDa. Under physiological circumstances, PCT is pro-
duced and then cleaved by a speci¢c protease to calcitonin
and katacalcin in C-cells of the thyroid gland. However,
strongly increased plasma concentrations of PCT were de-
tected in patients with thermal injury, in children with bacte-
rial meningitis, and in patients with sepsis and severe infection
[1^4].
In comparison to that of sepsis patients (1000^100 000 pg/
ml), the concentrations of PCT in the plasma of healthy blood
donors were found to be very low (around 40 pg/ml) [5,6]. In
in vivo studies, increased PCT levels could be measured after
endotoxin injections in healthy volunteers [7]. Due to these
characteristics and to its very long half-life time in the blood
(25^30 h), PCT is routinely used as a parameter for the diag-
nosis of severe bacterial and fungal infections and for media-
tor-directed therapy of sepsis [4,6].
Recently, it was found that not PCT(1-116) but only the
truncated form, lacking the dipeptide Ala-Pro, PCT(3-116), is
present in the serum of patients with bacterial sepsis (Dr.
Andreas Bergmann, BRAHMS Diagnostica GmbH, personal
communication). The function of serum PCT(3-116) in septi-
cal and healthy status as well as the importance of the N-
terminal truncation of PCT and the identity of the enzyme
responsible for that truncation are completely unknown as
yet. However, it is highly probably that the dipeptidyl pepti-
dase IV (DP IV, EC 3.4.14.5, CD26) cleaves PCT(1-116). DP
IV is a 110 kDa glycoprotein, which catalyzes the release of
N-terminal dipeptides from oligo- and polypeptides preferen-
tially with proline, hydroxyproline and, with less e⁄ciency,
alanine in the penultimate position [8^10]. In the blood circu-
lation, this enzyme is expressed on the surface of endothelial
and di¡erent hematopoietic cells and is also present in a solu-
ble form in the plasma [11]. Since DP IV has this unique
enzymatic speci¢city compared with other exopeptidases and
it has access to serum PCT, we investigated whether PCT(1-
116) is a substrate of DP IV.
2. Materials and methods
2.1. Cloning and expression of PCT116 cDNA
The cDNA fragment encoding human PCT(1-116) was ampli¢ed by
PCR from human thyroid gland cDNA (Clontech, Palo Alto, CA,
USA) using the following oligonucleotide primers: 5P-CCG GGA
ATT CAG CTG CAC CAT TCA GGT CTG CCC TGG-3P and
5P-CCG GGA ATT CGG AGG AGT TTA GTT GGC ATT CTG
GGG C-3P (restriction enzyme recognition sites for EcoRI and PvuII
are underlined). Ampli¢cation was performed using Pfu DNA poly-
merase (Stratagene, La Jolla, CA, USA) and the puri¢ed PCR prod-
uct was cloned into pET-26b (Novagen, Madison, WI, USA) contain-
ing the T7lac promoter and a pelB leader peptide. The resulting
plasmid was veri¢ed by sequencing and used to transform
BL21(DE3) (Novagen). Expression of PCT(1-116) was induced at a
cell density of 0.6 A588 by addition of IPTG (1 mM ¢nal concentra-
tion). After 3 h, cells were harvested and the periplasmic fraction
containing PCT(1-116) was isolated by osmotic shock [12].
2.2. Puri¢cation of PCT(1-116)
The supernatant containing PCT(1-116) was ¢ltered (0.2 Wm) and
applied onto a 10U100 mm anion exchange chromatography column
(Poros HQ, Perseptive Biosystems, Framingham, MA, USA). The
protein was eluted with a 0^250 mM NaCl gradient in 20 mM Tris/
bis-Tris-Propan pH 7.0. Fractions were analyzed using the LUMI-
test0 PCT kit (BRAHMS Diagnostica GmbH, Hennigsdorf, Ger-
many); those containing PCT(1-116) were pooled and ¢nally puri¢ed
by reversed phase chromatography using a 4.6U100 mm Poros R2
column (Perseptive Biosystems) and a gradient of 5% acetonitrile,
0.1% tri£uoroacetic acid to 90% acetonitrile, 0.1% tri£uoroacetic
acid. After analysis by sodium dodecyl sulfate^polyacrylamide gel
electrophoresis (SDS^PAGE), fractions containing PCT(1-116) with-
out any contaminations were pooled and lyophilized. The identity of
the puri¢ed PCT(1-116) was con¢rmed by subjecting it to N-terminal
sequence analysis and mass spectrometry.
2.3. Human kidney DP IV
DP IV was puri¢ed from human kidney cortex. Membrane proteins
were solubilized by the addition of 1% Triton X-100 to the homogen-
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ized tissue for 1 h. Subsequently, a fractionated ammonium sulfate
precipitation was performed. The fraction between 50% and 65% sat-
uration, containing most of the DP IV, was used for further puri¢ca-
tion by means of three di¡erent steps of liquid chromatography. After
gel chromatography on Sepharose 6B, the pooled DP IV fractions
were applicated on a Sephadex A50 ion exchange column and eluted
with an increasing gradient of NaCl. The ¢nal polishing step was
performed on a FPLC Poros HQ ion exchange column. Resulting
DP IV has a speci¢c activity of 32 U/mg and shows no contamination
in a silver-stained PAGE.
2.4. Synthetic DP IV inhibitors, PCT(2-116)
The reversible DP IV inhibitor Lys[Z(NO2)]-thiazolidide and the
irreversible inhibitor Pro-ProP[OPh-4Cl]2 were kindly provided by
Dr. K. Neubert (Martin-Luther-University Halle/Wittenberg, Ger-
many). PCT(2-116) was a generous gift from BRAHMS Diagnostica
GmbH (Hennigsdorf, Germany).
2.5. Cleavage of PCT(1-116) by human kidney DP IV
Stock solutions of 1 mM PCT(1-116) and PCT(2-116) contained 1%
human serum albumin (HSA, protease-free, Sigma, Deisenhofen, Ger-
many) to reduce adsorption processes.
Samples of a total volume of 16 Wl, containing 15.5 pkat of human
kidney DP IV and 4 nmol PCT(1-116) peptide, or PCT(2-116) as
control, in 10 mM sodium phosphate assay bu¡er pH 7.4, were in-
cubated at 37‡C for up to 24 h. For the starting value, DP IV activity
in 2 Wl aliquots was stopped immediately by addition of 3 Wl 30 mM
phosphoric acid, pH 2.0 (stopping bu¡er). After 0.5, 2 and 9.5 h in 3 Wl
of the reaction mixture, the DP IV activity was also stopped with 3 Wl
stopping bu¡er. To achieve complete degradation of the substrate,
further DP IV (5.5 pkat) was added to the residual reaction mixture
and incubation was continued for further 14.5 h. All samples were
stored at 320‡C.
The formation of the dipeptide product Ala-Pro as a consequence
of PCT(1-116) degradation was determined by the method of capillary
zone electrophoresis (CE) using Biofocus 3000 (Bio-Rad, Mu«nchen,
Germany). The samples were injected by pressure onto a LPA coated
silica capillary (30 cm length, 50 Wm ID, Bio-Rad) ¢lled with 0.1 M
phosphate bu¡er pH 2.5 with linear polymer (Bio-Rad). The separa-
tion was performed with a voltage of 17 kV (positive to negative) and
monitored with UV absorption at 200 nm. For examination of the
in£uence of DP IV-speci¢c, synthetic inhibitors, samples were prein-
cubated with the inhibitor speci¢ed for 30 min at 37‡C before PCT(1-
116) was added and kinetics were performed as described.
2.6. Mass spectrometry analysis of DP IV-catalyzed PCT(1-116)
cleavage
Aliquots (2 Wl) of the 2 and 9.5 h sample were evaporated and mass
spectrometry analysis was performed by the Max-Delbru«ck-Centrum
(MDC, Berlin-Buch, Germany) using a Q-Tof mass spectrometer (Mi-
cromass, UK).
2.7. Edman sequence analysis of DP IV-catalyzed PCT(1-116)
cleavage
N-terminal Edman sequence analysis was performed by WITA
GmbH (Teltow, Germany). The 24 h sample was evaporated and
prior to the application onto a with polybrene (ABI Bio Brene Plus,
Applied Biosystems, Weiterstadt, Germany) pretreated Micro TFA
glass ¢ber ¢lter (Applied Biosystems) dissolved in 50% acetonitrile/
H2O. Six cycles of N-terminal Edman degradation were performed
with ABI Procice sequencer (Applied Biosystems).
3. Results
3.1. Hydrolysis of PCT(1-116) by puri¢ed human kidney
DP IV
Due to its N-terminal sequence with proline in the penulti-
mate position, PCT(1-116) is a putative substrate for DP IV.
Based on the method of capillary electrophoresis, we estab-
lished an assay for the examination of PCT(1-116) hydrolysis
by puri¢ed human kidney DP IV. Neither HPLC nor capillary
electrophoresis could separate PCT(1-116) from PCT(3-116).
Therefore, we monitored the formation of the N-terminal di-
peptide Ala-Pro. This product could be properly separated
from the large peptides PCT(1-116) and PCT(3-116) as well
as from the carrier protein HSA by means of CE (Fig. 1A).
However, since the UV absorption of the dipeptide Ala-Pro is
low, we needed to use high non-physiological concentrations
of PCT in the assay. For quanti¢cation of the enzymatic re-
action, the amount of Ala-Pro in the sample was set in rela-
tion to the amount of Ala-Pro formed by complete degrada-
tion after 24 h.
In Fig. 1A, the time course of the DP IV-catalyzed degra-
dation of PCT(1-116) is shown. After 9.5 h, 70% of the
PCT(1-116) was hydrolyzed. With the molar ratio of 1:250
for DP IV to substrate, used in our assay, the maximum turn-
over rate was calculated to 135 pmol/h. The incubation of
PCT(2-116) with DP IV revealed no cleavage products in
the electropherograms, indicating the speci¢city of the assay
used (Fig. 1B).
Furthermore, analysis of the 24 h sample by N-terminal
Edman sequence analysis clearly demonstrated that DP IV
cleaves full-length PCT(1-116) and that Ala-Pro is not re-
leased from shorter intermediary products. As expected, due
to the N-terminal sequence of PCT (Ala-Pro-Phe-Arg-Ser-
Ala-Leu-Glu), Ala (from Ala-Pro) and Phe (from PCT(3-
116)) were detected in the ¢rst cycle as the main products.
Pro and Arg were clearly detected in the second cycle and
Ser, Ala, Leu and Glu, corresponding to the sequence of
PCT(3-116), in the following cycles. In the third step, no
Phe was detected, indicating that PCT(1-116) was completely
hydrolyzed after 24 h of incubation (data not shown).
Moreover, mass spectrometry analysis con¢rmed these re-
sults. Two proteins with masses of 12 791.5 Da and 12 623.5
Da were found in the 9.5 h sample (theoretical masses of
PCT(1-116) and PCT(3-116) are 12 796.2 Da and 12 628 Da,
respectively), which shows a partial DP IV-catalyzed hydrol-
ysis of PCT(1-116) (data not shown).
3.2. In£uence of synthetic DP IV inhibitors on PCT(1-116)
cleavage
To clarify whether the cleavage of PCT(1-116) is done ex-
clusively by DP IV and not by a putative impurity in the DP
IV preparation used, further experiments were performed in
the presence and absence of two synthetic, highly speci¢c DP
IV inhibitors. Lys[Z(NO2)]-thiazolidide, a competitive inhibi-
tor with IC50 = 2.7 þ 0.3 WM [13], and the irreversible inhibitor
Pro-ProP[OPh-4Cl]2 (Ki = 18.6 WM) were used in concentra-
tions of 20 WM and 4 WM, respectively. As shown in Fig. 2,
both inhibitors were capable of preventing the DP IV-cata-
lyzed hydrolysis of PCT(1-116) almost completely.
4. Discussion
Di¡erent groups have shown the ubiquitous distribution of
the DP IV on the membrane of a variety of cells including
epithelial and endothelial cells and the exceptional high ex-
pression in intestine, kidney and liver [11]. In the circulation,
DP IV, which is identical with the T cell activation marker
CD26, is expressed on the surface of resting and activated T
cells, activated B cells and activated NK cells [10]. Further-
more, soluble forms of DP IV are described in the human
plasma [14,15].
DP IV is a type II membrane enzyme, which has an extra-
cellularly orientated catalytic domain with unique enzymatic
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speci¢city [8,9,16]. The penultimate N-terminal proline is
present in a number of peptides originating from the neuro-
endocrine system (e.g. substance P, L-casomorphine, neuro-
peptide Y, peptide YY, growth hormone-releasing factor)
and of cytokines and growth factors, such as IL-3, IL-5, IL-
10, IL-11, IL-13, GM-CSF, G-CSF, RANTES, LIF and
thrombopoietin [10,16,17]. This proline residue protects these
molecules from degradation by most aminopeptidases [8].
Short peptides as substance P and gastrin-releasing peptide
have been known as e¡ective substrates for DP IV [9]. In
contrast, none of the intact, full-length cytokines with proline
in the penultimate position has been identi¢ed as a DP IV
substrate although smaller peptides up to 24 amino acids,
containing the N-terminal sequence of cytokines (e.g. IL-1L,
IL-2, murine IL-6), were cleaved. The rate of DP IV-catalyzed
hydrolysis was negatively correlated with their chain length
[17].
Recently, DP IV/CD26 has been shown also to process a
Fig. 1. Incubation of PCT(1-116) (A) and PCT(2-116) (B) with DP IV. Aliquots of the reaction mixture were taken and applied to CE after
the incubation times indicated. Total cleavage was achieved by addition of further DP IV to the residual reaction mixture after 9.5 h and incu-
bation for a further 14.5 h (indicated as 24 h). The inset shows the complete scale of the y-axis (HSA, carrier protein; His, histidine, standard
for CE separation).
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number of chemokines including RANTES (regulated on ac-
tivation normal T cell expressed and secreted), SDF-1 (stro-
mal cell-derived factor-1), GCP-2 (granulocyte chemotactic
protein-2), MDC (macrophage-derived chemokine) and
others, generating naturally occurring truncated molecules
with a signi¢cantly altered biological activity [16]. These DP
IV substrates are proteins with a chain length between 69 and
75 amino acids.
PCT(1-116), a parameter for the diagnosis of severe bacte-
rial and fungal infections with the N-terminal sequence Ala-
Pro-Phe-Arg-Ser-Ala-, is also a potential substrate of DP IV.
Interestingly, only the N-terminal truncated PCT(3-116), lack-
ing the N-terminal dipeptide Ala-Pro, is found in high con-
centrations in patients with severe sepsis. Here, using the
method of CE, we demonstrated for the ¢rst time that human
DP IV is capable of catalyzing the hydrolysis of PCT(1-116)
in vitro. This was con¢rmed by mass spectrometry and N-
terminal sequence analysis. To our knowledge, this is the ¢rst
report about DP IV-catalyzed hydrolysis of a protein greater
than 75 amino acids.
Due to the length of 116 amino acids, the turnover rate of
this cleavage is relatively low (135 pmol/h for the molar ratio
1:250 for DP IV to PCT in the assay). In vivo, however, a
molar excess of DP IV compared to PCT is present. We
measured in the plasma of eight healthy volunteers DP IV
concentrations of 16.5 þ 2.9 nmol/l (data not shown). In pa-
tients with sepsis, together with membrane-bound DP IV,
highly expressed on di¡erent activated in£ammatory and en-
dothelial cells, the total DP IV activity in the circulation
should be high enough to be responsible for the truncation
of even a long substrate like PCT(1-116).
However, the biological relevance and the origin of the N-
terminal-truncated form of PCT, which is present in the serum
of patients with bacterial infections and sepsis, are unknown
as yet. Recently, PCT mRNA and protein expression was
proved in peripheral blood mononuclear cells [18]. Lipopoly-
saccharide, phytohemagglutinin and various proin£ammatory
cytokines (e.g. IL-1L, IL-6, TNF-K, IL-2), which have pro-
nounced stimulatory e¡ects on the PCT mRNA expression
of these cells [18], are also potent stimulators of DP IV ex-
pression and activity on T cells, B cells and NK cells [10].
These facts suggest the involvement of DP IV, expressed on
these activated immune cells as well as on endothelial cells,
and soluble DP IV of the serum, in the truncation of PCT(1-
116) in patients with bacterial infection and sepsis.
Current work is designed to locate the origin of PCT and to
correlate the occurrence of truncated PCT with that of DP IV
expression.
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